Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Related GALE
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of
UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

DateFirmActionFromTo
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Get Benzinga's Newsletters